335 filings
Page 3 of 17
144
Jared Gollob
9 Feb 24
Notice of proposed sale of securities
4:22pm
SC 13G/A
Atlas Venture Fund X, L.P.
9 Feb 24
Kymera Therapeutics / Atlas Venture Fund X ownership change
4:03pm
SC 13G/A
KYMR
Kymera Therapeutics Inc
8 Feb 24
Kymera Therapeutics / WELLINGTON MANAGEMENT ownership change
10:21am
SC 13G/A
BLK
Blackrock Inc.
29 Jan 24
Kymera Therapeutics / BlackRock ownership change
3:26pm
4
KYMR
Kymera Therapeutics Inc
23 Jan 24
Kymera Therapeutics / Jeffrey W. Albers ownership change
7:37pm
144
KYMR
Kymera Therapeutics Inc
23 Jan 24
Notice of proposed sale of securities
4:19pm
SC 13G/A
STT
State Street Corp.
23 Jan 24
Kymera Therapeutics / STATE STREET ownership change
10:31am
SC 13G/A
KYMR
Kymera Therapeutics Inc
10 Jan 24
Kymera Therapeutics / BAKER BROS. ADVISORS ownership change
4:52pm
4
KYMR
Kymera Therapeutics Inc
9 Jan 24
Kymera Therapeutics / MARK N LAMPERT ownership change
4:49pm
SC 13D/A
KYMR
Kymera Therapeutics Inc
9 Jan 24
Kymera Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change
4:45pm
4
KYMR
Kymera Therapeutics Inc
5 Jan 24
Kymera Therapeutics / Ellen Chiniara ownership change
5:15pm
8-K
KYMR
Kymera Therapeutics Inc
5 Jan 24
Kymera Therapeutics Announces Proposed Public Offering
4:11pm
424B5
KYMR
Kymera Therapeutics Inc
5 Jan 24
Prospectus supplement for primary offering
4:02pm
424B5
KYMR
Kymera Therapeutics Inc
4 Jan 24
Prospectus supplement for primary offering
4:06pm
8-K
KYMR
Kymera Therapeutics Inc
4 Jan 24
Regulation FD Disclosure
4:01pm
144
Ellen Chiniara
4 Jan 24
Notice of proposed sale of securities
9:29am
8-K
KYMR
Kymera Therapeutics Inc
4 Jan 24
STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024
7:08am
4
Nello Mainolfi
2 Jan 24
Kymera Therapeutics / Nello Mainolfi ownership change
5:43pm
4
KYMR
Kymera Therapeutics Inc
6 Nov 23
Kymera Therapeutics / MARK N LAMPERT ownership change
6:07pm
4
Nello Mainolfi
6 Nov 23
Kymera Therapeutics / Nello Mainolfi ownership change
6:00pm